Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy

Cancer Research

Volumn 59, Issue 6, 1999, Pages 1273-1277

  Won, Jonghwa ^a   Kim, Hongtae ^a   Park, Eun Jeong ^a   Hong, Yeonchul ^a   Kim, Seong Jin ^b   Yun, Yungdae ^a  

^a Mogam Biotechnology Research Institute   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; CELLULAR IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOMA; TUMOR GROWTH;

ANIMALS; DISEASE PROGRESSION; IMMUNOSUPPRESSION; MICE; MICE, INBRED C57BL; MUTAGENESIS; NEOPLASM TRANSPLANTATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; THYMOMA; THYMUS NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0033559577     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Sporn, M. B., Roberts, A. B., Wakefield, L. M., and Assolan, R. K. Transforming growth factor-β: biological function and chemical structure. Science (Washington DC), 233: 532-534, 1986.
2. Cheifetz, S., Hernandez, H., Laiho, M., ten Dijke, P., Iwata, K. K., and Massagué, J. Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J. Biol. Chem., 265: 20533-20538, 1990.
3. 2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ., 4: 115-123, 1993.
4. Zugmaier, G., Ennis, B. W., Deschauer, B., Katz, D., Knabbe, C., Wilding, G., Daly, P., Lippman, M. E., and Dickson, R. B. Transforming growth factor type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines. J. Cell. Physiol., 141: 353-361, 1989.
5. Glick, A. B., Lee, M. M., Darwiche, N., Kulkarni, A. B., Karlsson, S., and Yuspa, S. H. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev., 8: 2429-2440, 1994.
6. Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., and Akhurst, R. J. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell, 86: 531-542, 1996.
7. Park, K., Kim, S-J., Bang, Y-J., Park J-G., Kim, N. K., Roberts, A. B., and Sporn, M. B. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc. Natl. Acad. Sci. USA. 91: 8772-8776, 1994.
8. Sun, L., Wu, G., Willson, J. K. V., Zborowska, E., Yang, J., Rajkarunanayake I., Wang, J., Gentry, L. E., Wang, X-F., and Brattain, M. G. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem., 269: 26449-26455, 1994.
9. Kadin, M. E., Cavaille-Coll, M. W., Gertz, R., Massagué, J., Cheifetz, S., and George, D. Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc. Natl. Acad. Sci. USA, 91: 6002-6006, 1994.
10. Capocasale, R. J., Lamb, R. J., Vonderheid, E. C., Fox, F. E., Rook, A. H., Nowell, P. C., and Noore, J. S. Reduced surface expression of transforming growth factor β receptor type II in mitogen-activated T cells from Sezary patients. Proc. Natl. Acad. Sci. USA. 92: 5501-5505, 1995.
11. Wang, J., Han, W., Zborowska, E., Liang, J., Wang, X., Willson, J. K. V., Sun, L., and Brattain, M. G. Reduced expression of transforming growth factor β type I receptor contributes to the malignancy of human colon carcinoma cells. J. Biol. Chem., 271: 17366-17371, 1996.
12. Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., Brattain, M., and Willson, J. K. V. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science (Washington DC), 268: 1336-1338, 1995.
13. Frank, C. J., McClatchey, K. D., Devaney, K. O., and Carey, T. E. Evidence that loss of chromosome 18q is associated with tumor progression. Cancer Res., 57: 824-827, 1997.
14. Reiss, M., Santoro, V., de Jonge, R. R., and Vellucci, V. F. Transfer of chromosome 18 into human head and neck squamous carcinoma cells: evidence for tumor suppression by smad4/DPC4. Cell Growth Differ., 8: 407-415, 1997.
15. 1 by small cell lung cancer cell lines. Eur. J. Cancer, 30A: 2125-2129, 1994.
16. Barrack, E. R. TGFβ in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate, 31: 61-70, 1997.
17. Steiner, M. S., and Barrack, E. R. Transforming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol. Endocrinol., 6: 15-25, 1992.
18. Oft, M., Peli, J., Rudaz, C., Schwarz, H., Beug, H., and Reichmann, E. TGF-β1 and Ha-ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev., 10: 2462-2477, 1996.
19. Ueki, N., Ohkawa, T., Yokoyama, Y., Maeda, J., Kawai, Y., Ikeda, T., Amuro, Y., Hada, T., and Higashino, K. Potentiation of metastatic capacity by transforming growth factor-β1 gene transfection. Jpn. J. Cancer Res., 84: 589-593, 1993.
20. Nakashio, T., Narita, T., Akiyama, S., Kasai, Y., Kondo, K., Ito, K., Takagi, H. and Kannagi, R. Adhesion molecules and TGF-β1 are involved in the peritoneal dissemination of NUGC-4 human gastric cancer cells. Int. J. Cancer, 70: 612-618, 1997.
21. Ruegemer, J. J., Ho, S. N., Augustine, J. A., Schlager, J. W., Bell, M. P., McKean, D. J., and Abraham, R. T. Regulatory effects of transforming growth factor-β on IL-2-and IL-4-dependent T cell-cycle progression. J. Immunol., 144: 1767-1776, 1990.
22. Kasid, A., Bell, G. I., and Director, E. P. Fffects of transforming growth factor-β on human lymphokine-activated killer cell precursors. J. Immunol., 141: 690-698, 1988.
23. + T cells requires the coordinate action of interleukin-12 and IFN-γ and is inhibited by transforming growth factor-β. Eur. J. Immunol., 24: 793-798, 1994.
24. + T cell function. Jpn. J. Cancer Res., 84: 315-325, 1993.
25. Roszman, T., Elliott, L., and Brooks, W. Modulation of T-cell function by gliomas. Immunol. Today. 12: 370-374, 1991.
26. + T lymphocytes. J. Immunol., 146: 3289-3297, 1991.
27. 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA, 87: 1486-1490, 1990.
28. Wrana, J. L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X-F., and Massagué, J. TGFβ signals through a heteromeric protein kinase receptor complex. Cell, 71: 1003-1014, 1992.
29. Wieser, R., Wrana, J., and Massagué, J. GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J., 14: 2199-2208, 1995.
30. Heldin, C.H., Miyazono, K., and ten Dijke, P. TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature (Lond.), 390: 465-471, 1997.
31. Lopez-Casillas, F., Wrana, J. L., and Massagué, J. Betaglycan presents ligand to the TGFβ signaling receptor. Cell, 71: 1435-1444, 1993.
32. Lin, H.Y., Moustakas, A., Knaus, P., Wells, R.G., Henis, Y.I., and Lodish, H.F. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-β receptor. J. Biol. Chem., 270: 2747-2754, 1995.
33. Maeda, H., Tsuru, S., and Shiraishi, A. Improvement of macrophage dysfunction by administration of anti-transforming growth factor-β antibody in EL4-bearing hosts. Jpn. J. Cancer Res., 85: 1137-1143, 1994.
34. Maeda, H., and Shiraishi, A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol., 156: 73-78, 1996.
35. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
36. Lin, H. Y., Wang, X. F., Ng-Eaton, E., Weinberg, R. A., and Lodish, H. F. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell, 68: 775-785, 1992.
37. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. Production of high-titer helper-free retroviruses hy transient transfection. Proc. Natl. Acad. Sci. USA, 90: 8392-8396, 1993.
38. Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., and Sobol, R. E. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA, 93: 2909-2914, 1996.
39. Sun, L., and Chen, C. Expression of transforming growth factor β type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J. Biol. Chem., 272: 25367-25372, 1997.
40. McAdam, A. J., Felcher, A., Woods, M. L., Pulaski, B. A., Hutter, E. K., Frelinger, J. G., and Lord, E. M. Transfection of transforming growth factor-β producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive CTLs. J. Immunother., 15: 155-164, 1994.